In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 5 | 5 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 3 | 0 | 0 |
| 2M Ago | 0 | 2 | 2 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $96.45, a high estimate of $105.00, and a low estimate of $85.00. Witnessing a positive shift, the current average has risen by 5.25% from the previous average price target of $91.64.
Interpreting Analyst Ratings: A Closer Look
The standing of Edwards Lifesciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Matt Miksic | Barclays | Raises | Overweight | $101.00 | $100.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $99.00 | $94.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $89.00 | $92.00 |
| Rick Wise | Stifel | Raises | Hold | $85.00 | $83.00 |
| Adam Maeder | Piper Sandler | Raises | Neutral | $88.00 | $85.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $101.00 | $95.00 |
| Anthony Petrone | Mizuho | Raises | Buy | $105.00 | $95.00 |
| Vijay Kumar | Evercore ISI Group | Raises | In-Line | $92.00 | $86.00 |
| Joanne Wuensch | Citigroup | Raises | Neutral | $98.00 | $90.00 |
| Patrick Wood | Morgan Stanley | Raises | Overweight | $103.00 | $95.00 |
| Suraj Kalia | Oppenheimer | Raises | Outperform | $100.00 | $93.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Edwards Lifesciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Edwards Lifesciences compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Edwards Lifesciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Edwards Lifesciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Edwards Lifesciences analyst ratings.
Delving into Edwards Lifesciences's Background
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
Edwards Lifesciences: Financial Performance Dissected
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Edwards Lifesciences's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 9.5%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Edwards Lifesciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 22.02%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.11%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Edwards Lifesciences's ROA stands out, surpassing industry averages. With an impressive ROA of 3.68%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Core of Analyst Ratings: What Every Investor Should Know
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
